- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 239/28
Total number of patents in this class: 336
10-year publication summary
|
29
|
23
|
15
|
18
|
12
|
14
|
15
|
17
|
13
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| CHDI Foundation, Inc. | 105 |
11 |
| Corteva Agriscience LLC | 2654 |
11 |
| Novartis AG | 10481 |
9 |
| Syngenta Participations AG | 1642 |
8 |
| Theravance Biopharma R&D IP, LLC | 442 |
8 |
| BASF SE | 21149 |
7 |
| Boehringer Ingelheim International GmbH | 4587 |
7 |
| Syngenta Crop Protection AG | 6342 |
6 |
| Purdue Pharma L.P. | 495 |
6 |
| Bristol-myers Squibb Company | 4809 |
5 |
| Bayer AG | 3408 |
5 |
| Bayer Cropscience AG | 1955 |
5 |
| Incyte Corporation | 1039 |
5 |
| Merck Sharp & Dohme LLC | 3748 |
5 |
| Hoffmann-La Roche Inc. | 3603 |
4 |
| The Regents of the University of California | 20366 |
4 |
| Janssen Pharmaceutica N.V. | 3322 |
4 |
| Merck Patent GmbH | 5726 |
4 |
| Empirico Inc. | 96 |
4 |
| Syngenta Limited | 440 |
3 |
| Other owners | 215 |